ESA e-Bulletin

Current e-Bulletin

ESA e Bulletin 9 March 2017

 

Archived e-Bulletin

ESA e Bulletin 23 February 2017

ESA e Bulletin 3 February 2017

ESA e Bulletin 13 January 2017

ESA e Bulletin 23 December 2016

ESA e Bulletin 10 November 2016

ESA e Bulletin 26 October 2016

ESA e Bulletin 7 October 2016

ESA e Bulletin 30 September 2016

ESA e Bulletin 15 September 2016

ESA e Bulletin 6 September 2016

ESA e Bulletin 15 August 2016

ESA e Bulletin 28 July 2016

ESA e Bulletin 4 July 2016

ESA e Bulletin 14 March 2016

ESA e Bulletin 25 February 2016

ESA e Bulletin 16 February 2016

ESA e Bulletin 25 January 2016

ESA e Bulletin 19 November 2015

ESA e Bulletin 9 November 2015

ESA e Bulletin 23 October 2015

ESA e Bulletin 6 October 2015

ESA e Bulletin 14 September 2015

ESA e Bulletin 21 August 2015

ESA e-Bulletin 13 August 2015

ESA e Bulletin 30 July 2015

ESA E-Bulletin 27 July 2015

ESA e-Bulletin 25 June 2015

ESA e-Bulletin 18 June 2015

ESA e-Bulletin 9 June 2015

ESA e-Bulletin 4 June 2015

ESA e-Bulletin 21 May 2015

ESA e-Bulletin 12 March 2015

ESA e-Bulletin 26 February 2015

ESA e-Bulletin 12 February 2015

ESA e-Bulletin 30 January 2015

ESA e-Bulletin 15 January 2015

ESA e-Bulletin 25 November 2014

ESA e-Bulletin 6 November 2014

ESA e-Bulletin 23 October 2014

ESA e-Bulletin 4 September 2014

ESA e-Bulletin 2 September 2014

ESA e-Bulletin 29 August 2014

ESA e-Bulletin 22 August 2014

ESA e-Bulletin 14 August 2014

ESA e-Bulletin 5 August 2014

ESA e-Bulletin 30 July 2014

ESA e-Bulletin 25 July 2014

ESA e-Bulletin 22 July 2014

ESA e-Bulletin 8 July 2014

ESA e-Bulletin 24 June 2014

ESA e-Bulletin 3 June 2014

ESA e-Bulletin 20 May 2014

ESA e-Bulletin 13 May 2014

ESA e-Bulletin 8 May 2014

ESA e-Bulletin 29 April 2014

ESA e-Bulletin 10 April 2014

ESA e-Bulletin 11 March 2014

ESA e-Bulletin 4th March 2014

ESA e-Bulletin 25 February 2014

ESA e-Bulletin 11 February 2014

ESA e-Bulletin 21 January 2014

ESA e-Bulletin 29 November 2013

 

 

Q Stream Online Professionalism Program

The RACP Online Professionalism Program (OPP) is a free online learning program that is designed to enhance physician’s practice and performance. The program content is based on real scenarios, developed by RACP Fellows with the aim to challenge physician thinking and improve professional practice.

The OPP is delivered by Qstream - an interactive learning platform -which disseminates case studies via email at spaced intervals. Qstream is developed by the Harvard Medical School and has been shown to increase knowledge retention, change on-the-job behaviours and improve patient outcomes. Email notifications prompt users to respond to case studies and each question takes just five minutes to complete. This flexibility means that users are free to engage and learn in their own time via desktop or mobile. Users also have the option to discuss the case studies and share opinions with others through the secure, online discussion boards.

OPP courses are developed under and focus on various domains within the SPPP (Supporting Physicians’ Professionalism & Performance) framework. Previous OPP courses delivered by RACP include: Modern Workplace Challenges and Diagnostic Error. Several new courses will be released in 2017.

Download flyer regarding the Diagnostic Error 2017 Qstream course. It would be greatly appreciated if you would consider circulating this to your members (who are also members of RACP).

Registration is open to RACP Fellows and Advanced ​Trainees.

Registrations for the Diagnostic Error 2017 course close Wednesday, 15 March 2017, or earlier if full.

If you would like any further information regarding these sessions please contact sppp@racp.edu.au.

 

FUNDING GRANTS FOR WOMEN’S LEADERSHIP DEVELOPMENT

Women & Leadership Australia (WLA) is administering a national initiative to support the development of female leaders across the health sector.

The initiative is providing women working in health with grants for leadership development.

Expressions of interest are being sought until 9 March, 2017.

Download further information

Pfizer’s Independent Grants for Learning & Change (IGLC) programme for endocrinology

What does the IGLC programme cover?

Pfizer’s IGLC programme aims to provide grants for projects which seek to improve patient outcomes through the delivery of measurable, educational programmes and / or quality improvement initiatives.

Who can apply for an IGLC grant?

This programme is open to healthcare providers, quality improvement experts and stakeholders involved in the multidisciplinary care of patients within the field of endocrine in Europe, Australia and New Zealand.

Applications are open from 22 February 2017

Download further information

Attention clinical endocrinologists:

The RACP is undertaking a trial of multisource feedback (MSF) as part of the process of continuing professional development. The details are outlined in the accompanying document. If you are interested in participating in this trial please email Multisource.Feedback@racp.edu.au or call on +61 2 8247 6203. Registration is open until 31st March 2017.

Download document

2017 Workers Compensation Medical Practitioners Fees Order

The New South Wales State Insurance Regulatory Authority have released a document outlining the maximum fees chargeable by medical practitioners providing care under the Workers Compensation Act 1987.

Download document

 

Andrology Symposium

“Improving Men’s Health - Research Horizons in Andrology”

Monash Medical Centre, Clayton, Victoria

Saturday 28th November

8:30 – 5:00 pm

This is an initiative of the DFG-funded PhD training program joint between Monash University, Melbourne and Justus-Liebig University in Giessen, Germany, with the title "Molecular Pathogenesis of Male Reproductive Disorders".

This one day Symposium follows on from our annual scientific review and is intended to draw together our National and International colleagues who will collectively provide an update on clinical and basic research in Andrology. This will be a unique opportunity for a day of discussion of the Andrology field and how we might find way to move the field forward in the future.

Registration is free (http://goo.gl/forms/4c06zEIyvW) and there will be an opportunity for students to present their data in poster format within the program.

DOWNLOAD FLYER

International Society of Endocrinology Logo

ISE Members Update

September, 2016

Download ISE Members Update

Download ISE Members Update October 2016

Download ISE Members Update January 2017

 

GH Submission

A working group from the Endocrine Society of Australia and Australasian Paediatric Endocrine Group in conjunction with pharma have submitted an application for a listing for growth hormone treatment of severe adult growth hormone deficiency on the Pharmaceutical Benefits Scheme. Submissions from the public are invited by the Pharmaceutical Benefits Advisory Committee and may strengthen the application. Could clinical ESA members who have patients that will advocate for adult growth hormone replacement consider forwarding them the attached letter (drafted by Professor Ken Ho) inviting them to support the application. The deadline for public submissions is October 5, 2016.

Download letter inviting public submission to PBAC

PBAC meeting agenda

 

ESA Annual General Meeting 2016

Audited accounts 2016

AGM Agenda 23 August 2016

AGM Minutes 25 August 2015

Assessing Fitness to Drive 2016 Information Kit

The National Transport Commission and Austroads has announced the release of Assessing Fitness to Drive 2016, a new edition of national medical standards for driver licensing, which will come into effect on 1st October 2016.

Download information kit

 

Nominations for ESA Council 2016-2020

Nominations are now called for election to membership of the Council of the Endocrine Society of Australia.

At the 2014 election the following were elected for four years until 2018:
Bu Yeap, Nicolette Hodyl, Belinda Henry, Chen Chen and Craig Harrison

Council members reaching the end of their terms in 2016 are Helena Teede (who will stay on for the next year in the role of past-president), Tim Cole, Ashim Sinha and Morton Burt. These members can stand for re-election if they wish.

Warrick Inder will take on the role of President for two years, then past-president for one year.

Therefore, in the 2016 election, those elected will stay on ESA Council for 4 years until 2020. At least 4 states must be represented on the Committee.

A nomination form is included below for any ESA member wishing to nominate for election to ESA Council for 2016-2020. Nominees must be a financial member of the Society, and be nominated by two financial members of ESA. The primary requirement of a committee member is an interest in assisting with the work of ESA in promoting endocrine research and practice in Australia.

Nominations for election to the Society must reach the secretary of the ESA, A/Prof Tim Cole, 145 Macquarie Street, Sydney, NSW 2000 by 5:00 pm, Friday 1st April 2016.

Further details regarding the Committee of ESA, and procedures for elections to the committee can be found at the ESA website: http://www.endocrinesociety.org.au/constitution.htm

DOWNLOAD NOMINATION FORM

 

Description: Macintosh HD:Users:penelope 1:Library:Mobile Documents:com~apple~CloudDocs:MPH:Dissertation:Ethics :Ethics - Approved Docs:New Ad Materials:profile picture-01.png

Do you identify as trans* and are 14-25? Or, are you a parent/guardian of a trans* young person under the age of 25? Change the way services are provided to trans* young people in Australia - have your voice heard!

 

Trans* Pathways are currently conducting a study looking into the mental health and barriers to accessing services for trans* young people in Australia. The survey is directed to both trans* young people (aged 14-25) and parents/guardians of trans* young people under the age of 25. We hope that this research will help to inform policies, health professionals, other researchers, parents of trans* individuals, other trans* young people and the wider community about how relevant services can best meet the needs of trans* young people.

This research is a collaboration between the University of Western Australia, Telethon Kids Institute, Curtin University, YouthLink and the Freedom Centre.

Survey Link: bit.ly/transpathways

If you have any questions, please contact Penelope Strauss onpenelope.strauss@uwa.edu.au.

Precision Medicine in Metabolic Disease

Programme

 

 

RACP Expression of Interest: DoH Biosimilars Awareness Initiative Reference Group

The Department of Health is seeking representatives for their Biosimilars Awareness Initiative (BAI) Reference Group, and has invited the College to participate.

The Reference Group participants are being asked to represent and provide information on the needs and interests of their members.

As your specialty is highly relevant to biosimilars matters, we are asking for your support in promoting this opportunity to Fellows to represent their College on this Reference Group. We would appreciate it if you would circulate the attached Expression of Interest.

Please note that we have been provided with a very tight timeframe for this nomination. The College will be taking applications until COB Thursday 18 February. EOI forms and CVs can be submitted to policy@racp.edu.au.

Download: Biosimilars Awareness Inititative
Consultation structure

TGA web statement re: Medtronic MiniMed Sure-T infusion sets

The TGA recently published information regarding Medtronic MiniMed Sure-T infusion sets. The TGA's statement can be found at http://www.tga.gov.au/alert/medtronic-minimed-sure-t-infusion-sets

Medicines Australia Code Edition 18 transparency initiative

Download information about the new Code of Conduct transparency initiative commencing on 1 October 2015.

Frequently asked questions

Communication campaign

Website

PBAC request for Nomination for Reference Group – Ezetimibe review

The Pharmaceutical Benefits Advisory Committee (PBAC) intends to establish a Reference Group to conduct a post-market review of Ezetimibe, in terms of its cost-effectiveness in the context of the latest available evidence and best clinical practice.

All post-market reviews follow a standard process detailed in the Post-market Review Framework, available at: http://www.pbs.gov.au/info/reviews/subsidised-medicines-reviews. The Reference Groups will provide clinical, technical, consumer and industry advice to inform the reviews. Please see the attached Expression of Interest (EOI) form for further information.

The College has been invited to nominate a representative to participate in this review and, therefore, requests that you circulate this expression of interest to your membership. You may have already been approached by the PBAC on this matter, but we would like to seek expressions of interest from Fellows of your society, who are also members of the RACP. Concurrently, we will also seek expressions of interest from our Policy Reference Group members.

DOWNLOAD the EOI form for this nomination and the RACP Code of Conduct. Interested Fellows must complete and submit the EOI form and a CV to racpconsult@racp.edu.au by 5pm Thursday, 26 November.

If you have any queries, please do not hesitate to contact racpconsult@racp.edu.au.

ICE/CSE 2016 - Call for Program Suggestions Reminder:

The Program Organising Committee for the joint International Congress of Endocrinology and the Chinese Society of Endocrinology meeting (ICE/CSE 2016) is especially interested in your member’sideas for topics and speakers for the scientific sessions at ICE/CSE 2016 to ensure they craft a content rich and diverse program, reflective of our global endocrine community. Please forward this to your members and encourage them to submit their suggestions via the ICE/CSE 2016 website:http://www.ice-cse2016.org/en/page.asp?hid=&pageid=75.htmlor by using the attached form and sending toice-cse@comtecmed.com. The deadline for receipt of all suggestions is 31 July, 2015.

Download suggestion form

Announcing the 18th ASEAN Federation of Endocrine Societies Congress:

Hosted by the Malaysian Endocrine and Metabolic Society (MEMS) and chaired by our very own Executive Committee Member, Prof Dr Nor Azmi Kamaruddin, ISE are delighted to be supporting their regional partners at AFES 2015 being held 10th – 13th December 2015 at the Kuala Lumpur Convention Centre. Through a series of sponsored symposia and meet the professor sessions ISE will contribute to an exciting program themed around ‘Advancing the Frontiers of Endocrinology in Southeast Asia’. See the attached flyer for more details or visit www.afes2015.com. Benefit from early bird registration rates before 31st August 2015!

Download AFES poster

RACP info: PBS s100 changes for botulinum toxin

The Department of Health has recently announced changes for the PBS regarding botulinum toxin. Initially the changes were to be introduced from 1 July 2015 but after subsequent consultations this has now been pushed back to 1 September 2015.

The Department has now provided a 1 page FAQ on the changes.

FAQ

RCT of Testosterone for Androgen Deficiency-Like Symptoms (T4ADS) Study

The Andrology Department of Concord Hospital is conducting a randomised, double-blind, placebo-controlled, choice-extension, three phase cross-over study to evaluate testosterone treatment for androgen deficiency-like symptoms in men aged 40 years and above. The study aims to evaluate whether (a) testosterone is superior to placebo for improving androgen deficiency-like symptoms during 6 weeks of daily transdermal gel application and (b) if participants’ choice of preferred treatment has reproducible effects.

Potential participants should have lethargy or low energy symptoms and/or sexual dysfunction and think they may be testosterone deficient or wish to try testosterone treatment. Prior measurement of androgen levels is not necessary. Participants will be applying a transdermal gel daily and attend reviews at Concord Hospital at 3 weekly intervals for a total of 11 visits over 6 months. At visits, they will complete questionnaires and have blood sampled.

Interested participant should contact the Andrology Department at Concord Hospital at 97677222.

T4ADS advertisement

ADULT MEDICINE DIVISION COUNCIL Meeting 02-2015 C O M M U N I Q U E
The following Communiqué reports on the business addressed at the Adult Medicine Division Planning Day held on Thursday 9 July and the AMD Council meeting held on Friday 10 July 2015.

Download communique

Overseeing biosimilar use - CATAG release of Guiding Principles

Biological drugs such as proteins and peptides are produced by complex processes that include the use of recombinant protein expression in various organisms. Because of this complexity, the same biological produced by a different drug company after a patent expires is not identical despite having the same amino acid sequence. For example, there may be differences in post-translational modifications and trace impurities, and these may have biologically relevant effects. These copies are therefore called biosimilars rather than generics and it cannot be assumed that they are identical in all ways to the original. This is particularly relevant to endocrinologists as the first biosimilar insulin (of glargine insulin) has been approved in the EU, has tentative approval in the US, and the PBAC has recommended including it on the PBS here. The document provides guidelines for the use of biosimilars in Australian hospitals.

Download document

Direct Healthcare professional Communication: Risk of Diabetic Ketoacidosis during Treatment with Sodium Glucose Co-transporter 2 inhibitors

The purpose of this letter is to inform you of the new safety information for prescription medicines containing canagliflozin, dapagliflozin, or empagliflozin, which are inhibitors of sodium glucose co-transporter 2 (SGLT2) approved as oral antihyperglycemic agents for the treatment of patients with type 2 diabetes.

Download letter

Managing Medicines Access Programs

The Council of Australian Therapeutic Advisory Groups (CATAG) is writing to advise you of the completion and publication of theGuiding Principles for the governance of Medicines Access Programsin Australian hospitals. The Guiding Principles will beavailableon the CATAG websitewww.catag.org.auand can be downloaded in a pdf format.

Managing Medicines Access Programs Endocrine Society of Australia

OKA10428 CATAG Guiding Principles for Australian Hospitals FINAL pdf

 

Dexamethasone 0.5mg tablet shortage

The Pharmacy at Princess Alexandra Hospital in Brisbane has alerted the Endocrine Society of Australia of a potential shortage of dexamethasone 0.5 mg tablets, used for diagnostic testing and occasionally therapeutically. Please check your local pharmacy for details of supply in your area. An alternative supply has been found, which will require an SAS application. Click on form

New Editor-in-Chief for JOE & JME

Applications are invited for EDITOR-IN-CHIEF for Journal of Endocrinology & Journal of Molecular Endocrinology.
The Society for Endocrinology invites applications for the role of Editor-in-Chief for a five-year term starting in August 2015.

Applications are due by 1 February 2015, and should be emailed to David Ray, Chair of the Society for Endocrinology Publications Committee (joe@bioscientifi ca.com).

Candidates will be shortlisted and interviews will be held in March 2015.

Click for further information

Medicare Benefits Schedule – Changes to pathology services

From 1 November 2014, there will be a number of changed to the Pathology Services Table (PST) of the Medicare Benefits Schedule to give effect to recommendations by the Medical Services Advisory Committee.  These relate to vitamin D, B12, folate, HbA1c for the diagnosis of diabetes mellitus, and genetic testing for hereditary mutations in the RET gene.

Click for further information

Amendments to a range on MBS items to remove gender specific language

Click on: Removal of gender specific language from the Medicare Benefits Schedule (MBS)

 

Research into effect of pesticides on frogs

My research team and I have launched a crowd funding project in an attempt to raise money to fund our research into the effect of some common insecticides on the thyroid hormone balance and the development of amphibians. Amphibians, one third of which is already threatened with extinction, are particularly vulnerable to the effects of pollutants because of their aquatic lifestyle and their permeable skin. These pesticides have been detected in Australian streams, home to some of the world's unique frogs. The pesticides are also used in a range of other countries, all over the world - including the US, Europe and South Africa.

We thought that this is a topic that would be of interest to ESA members. If deemed appropriately, you could help us raise the funds by getting the word out and disseminating the link:www.pozible.com/freethefrog via social media or newsletters. We have 60 days to raise the money if the project is to be successful, so any contribution you could make is enormously appreciated! Thank you very much in advance!

Bert De Groef, Lecturer & Postgraduate Coordinator, Latrobe University

Free the frog flyer

Substitute for Synacthen during shortage of supply

Novartis is supplying a substitute product for Synacthen 0.25mg ampoules (tetracosactrin) while there is a current shortage of supply of the registered goods in Australia. This interim measure is being taken in consultation with the Therapeutic Goods Administation.

Click on link for further information Substitute for Synacthen during shortage of supply

 

Neo Mercazole approved for supply under S19A of the Therapeutic Goods Act

Link Medical Products would like to advise that due to an ongoing shortage of carbimazole 5mg tablets, and to maintain supply, the TGA has granted approval to supply an alternative product until 30 November 2014, under subsection 19A of the Therapeutic Goods Act, 1989, the Act.

Approval has been granted to supply product which is approved in New Zealand. This is called NeoMercazole 5mg tablets, and while this product has the same active ingredient, carbimazole, as the regular Australian product it is NOT registered in Australia.

As the product is unregistered, the Australian Registration number, AUST R, which is printed on this product’s label, has been struck out in such a way that the number of tablets remains clear. The label carries the Australian sponsor's name and address.

Please Click here for the approved Dear Healthcare Professional letter and a copy of the patient leaflet or CMI:

DHCPL NeoMercazole Approved Neomercazole CMI Australia

Julia Guinan

Senior Regulatory Affairs Associate

Link Pharmaceutical Group (Australia & New Zealand)

julia.guinan@linkhealthcare.com.au

Important information regarding strontium ranelate (PROTOS) for Healthcare Professionals

Endocrine Society Statement: The Risk of Cardiovascular Events in Men Receiving Testosterone Therapy

Link to Endocrine Society statement

ESA Council notes the recent statement by the US Endocrine Society and supports its dissemination for the consideration of ESA members.

The Council also notes the contribution of ESA members to current and ongoing research in this area (1,2), and supports the call for large scale, prospective RCTs to clarify the role of testosterone therapy in older men.

Refs:

1. Yeap B.B., Alfonso H., Chubb S.A.P., Handelsman D.J., Hankey G.J., Almeida O.P., Golledge J., Norman P.E., Flicker L. In older men an optimal plasma testosterone is associated with reduced all-cause mortality, and higher dihydrotestosterone with reduced ischaemic heart disease mortality, while estradiol levels do not predict mortality. Journal of Clinical Endocrinology and Metabolism: 2014; 99: E9-E18.

2. Wittert G.A. on behalf of the T4DM Study Group. Rationale and design of a trial for the use of testosterone (T) for prevention of type 2 diabetes in men: The T4DM Trial. Abstract P-1959 presented at the World Diabetes Congress, Melbourne 2013. ANZ Clinical Trial Registry ACTRN12612000287831.

 

EDM Case Reports

Endocrine Society of Australia is delighted to announce a collaboration with Bioscientifica on their new open access publication, Endocrinology, Diabetes & Metabolism Case Reports.

Members of ESA receive a 20% discount on the open access publishing when publishing case reports in the open access publication; Endocrinology, Diabetes & Metabolism Case Reports(submit online via www.edmcasereports.com).

Endocrinology, Diabetes & Metabolism Case Reports is a unique, open access resource that publishes and links together case reports, enabling practitioners to communicate findings, share knowledge and convey medical experiences efficiently and effectively; furthering both medical education and clinical practice. The search and browse functionality enables fluid navigation between case reports, facilitating discovery, connections and comparisons; making it the go-to resource across all the many disciplines intersecting with endocrinology, diabetes and metabolism.

EoIs sought for Health in All Policies Working Group

Expressions of Interest are currently being sought from Fellows for membership of the College’s Health in All Policies (HiAP) Working Group. HiAP is an approach to policy making that places ‘health’ as a key decision-making factor in all areas of policy. It seeks to systematically take into account the health and health-system implications of public policy decisions, looks for synergies between policy portfolios to improve population health and health equity, and assesses potential harmful health impacts from policies.

The purpose of the HiAP Working Group, which is being established by the College Policy and Advocacy Committee, is to develop and articulate a College position on HiAP.

To apply, please complete the application form and send it and a copy of your c.v. to policy@racp.edu.au. Please direct any queries to Dianne Bennett on +61 2 9256 9609.

Deadline: Friday 31 January 2014

Application form

 

News

Information regarding FreeStyle Lite blood glucose test strips

The TGA recently published information regarding a recall of FreeStyle Lite blood glucose test strips. The TGA's statement can be found at http://www.tga.gov.au/safety/alerts-device-freestyle-lite-blood-glucose-test-strips-131122.htm

 

ENDOTEXT

May we take a moment of your time to introduce two wonderful web-books.  BothWWW.ENDOTEXT.ORG and WWW.THYROIDMANAGER.ORG are authoritative, comprehensive, non-biased, constantly updated, and most importantly, FREE.  Our web -books are written by by more than 400 authors from around the world, and carefully edited by 20 highly regarded clinician-scientists. They are WRITTEN BY DOCTORS, FOR DOCTORS. The books are the equivalent of about 4000 printed pages, and all material can be freely downloaded for personal use and for teaching. We have been on line for over 12 years, and receive up to 80,000 hits each day by 4-6000 readers.

If this sounds too good to be true, please take a look and judge for yourself. You will find they are exceptional, and that there is no catch. The goal of our team is uniquely to support the best practice of endocrinology around the world. We write this Email to you since we know that many endocrinologist, general physicians, pediatricians, surgeons, nurse practitioners, and trainees would find these websites useful, but do not know they exist.

We would love to hear any comments about or suggestions for the websites after you look them over.

Very best regards, Leslie J De Groot, MD, for the ENDOTEXT and THYROIDMANAGER teams.

ldegroot@earthlink.net
WWW.ENDOTEXT.ORG    WWW.THYROIDMANAGER.ORG

International Society of Endocrinology Annual Newsletter

Download the 2013 Newsletter.

TGA statement regarding Contact Detach infusion sets

The TGA recently published information regarding Contact Detach infusion sets. The TGA's statement can be found at http://www.tga.gov.au/alert/contact-detach-infusion-sets

ESA 2015 AGM

ESA Audited accounts 2015

ESA AGM Agenda 25 August 2015

ESA AGM minutes 26 August 2014

 

Potential for social media to act as a medium for imporving the links between researchers and clinicians

Explanatory Statement